Vectura Group Stock price

Equities

VEC

GB00BKM2MW97

Delayed London S.E. 11:35:22 2021-10-18 am EDT 5-day change 1st Jan Change
164.8 GBX -.--% Intraday chart for Vectura Group -.--% -.--%
Sales 2019 178M 225M Sales 2020 191M 241M Capitalization 739M 934M
Net income 2019 -22M -27.81M Net income 2020 122M 154M EV / Sales 2019 2.8 x
Net cash position 2019 66.5M 84.06M Net cash position 2020 74.4M 94.05M EV / Sales 2020 3.49 x
P/E ratio 2019
-27.3 x
P/E ratio 2020
6.2 x
Employees -
Yield 2019 *
-
Yield 2020
-
Free-Float 0%
More Fundamentals * Assessed data
Dynamic Chart
3 years
109.80
Extreme 109.8
176.00
5 years
59.10
Extreme 59.1
176.00
10 years
59.10
Extreme 59.1
216.78
More quotes
Managers TitleAgeSince
Director of Finance/CFO - -
Chief Operating Officer - 17-06-30
Chief Tech/Sci/R&D Officer - 16-05-31
More insiders
Vectura Group plc is engaged in research, development and commercialization of therapeutic products and drug delivery systems for human use. The Company's products include Ultibro Breezhaler (European Union (EU) and Rest of World (RoW)) - LABA-LAMA; Seebri Breezhaler (EU and RoW) - LAMA; AirFluSal Forspiro (EU and RoW) - ICS-LABA; ADVATE (Global) - Antihaemophilic Factor (Recombinant); Adept (Global) - Icodextrin; Anoro Ellipta (Global) - LAMA-LABA; Relvar Ellipta/Breo Ellipta (Global) - ICS-LABA, and Incruse Ellipta (Global) - LAMA. Its product pipeline includes VR588, VR475, VR647, VR942, VR179, VR736, VR096, VR876, VR315, VR506, VR632, Seebri Neohaler and VR465. Its dry powder inhalers (DPI) include GyroHaler, Lever-operated, Open-inhale-close and Unit Dose DPI. Its smart nebuliser delivery systems provide targeted inhalation therapy for applications where precise and targeted delivery of a drug to the lungs is needed. Its smart nebulizer delivery systems include AKITA JET and FOX.
Sector
-
More about the company
  1. Stock
  2. Equities
  3. Stock Vectura Group - London S.E.